“The current circumstance has exposed some structural weaknesses from the EU’s medicines offer chain as well as a superior dependence on non-EU nations around the world for active pharmaceutical ingredients,” Kyriakides mentioned. She recommended that supply chain troubles be resolved in an EU pharmaceutical strategy anticipated being release